The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Please sign up for SocialPicks site access - it's free!

 Momenta Pharmaceuticals Inc.  (MNTA) Trade Now »     Rate MNTA  -  Discuss MNTA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate MNTA:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

MNTA: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Opinion: Pathway for FOBs Should Balance Need for Competition and Need for Innovation Graphic_rating_buy MNTA
Mikerun
73%
This story was written by James Bianco, M.D., prinicipal founder, CEO, and director of Cell Therapeutics (CTIC), which is a member of the ETF Innovators Emerging Bio-Pharma Index:
                      
Related Article on Momenta Pharma (MNTA) by Mike Havrilla:
 
<> President Obama's first budget calls for the creation of a regulatory pathway for the creation of follow-on, or biosmiliar, biologics. This is obviously now the most hi...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/12/09 Comment


Three Oversold Healthcare Catalyst Stocks Graphic_rating_buy MNTA
Mikerun
73%
With the S&P 500 SPDR ETF (SPY) trading about 8% below its 50-day moving average (DMA), I went in search of oversold healthcare stocks trading at least 16% below their 50 DMA which have potential catalysts within the next six months that may provide some very nice returns.
 
<> The Healthcare Sector SPDR (XLV) is trading about 12% below its 50 DMA amidst concerns of sweeping healthcare reform that would threaten the profits of health insurers, managed care companies, big pharma, and biotechs – although such concerns may be overblown given the failed attempts at large scale healthc<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/12/09 Comment


Momenta Pharma's Three-Part Strategy Graphic_rating_buy MNTA
Mikerun
73%

Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB).

http://www.biomedreports.com/blog/Momenta-Pharmas-Three-Part-...

<> <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awa...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/06/09 Comment


Big Pharma Goes Generic Graphic_rating_buy MNTA
Mikerun
73%
Big Pharma Goes Generic edit
<> <> <> <> <> <> Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/26/09 Comment


Healthcare Hot Spots Beyond Stem Cells Graphic_rating_buy MNTA
Mikerun
73%
Beyond Stem Cells: Healthcare Hot Spots
 
With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM).
 
 
<> Below are three additional areas and associated companies for investors to consider in the search of the next hot s...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/26/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
RIMM Research in Motion Ltd
IBM International Business Machines Corp
RIO Companhia Vale Do Rio Doce
AIG American International Group Inc.
CSCO Cisco Systems Inc
SIRI Sirius Satellite Radio Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on MNTA

Visit streetinsider.com


Discussion Wall + Add  
amritadas   (+0.00%)
A FREE report on upcoming FDA decision for small ca.. - FDA decision date coming up this month for small cap company's Pain drug. If the FDA approves the drug, the peak sales could reach over 200% of the com...
+   0 replies


More Resources

Graphic_arrow1 About Momenta Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch